特拉佐代谢途径的表征和特定物种的特征
Vanessa Petrucci1, Patrizia Dragone1, Marcello C Laurenti1
1Angelini Pharma S.p.A., Rome, Italy.
特拉佐的新陈代谢在物种之间有很大差异,人类肝酶的清除速度较慢. 了解这些差异,特别是CYP3A4A4的差异.
科学领域:
- 药理学 药理学是指药理学的学科.
- 药物新陈代谢 药物新陈代谢
- 生物化学 生物化学
背景情况:
- 特拉佐是治疗主要抑郁症 (MDD) 的抗抑郁药.
- 它的新陈代谢涉及多个细胞染色体P450 (CYP) 异型.
- 关于特拉佐生物转化和物种间差异的研究有限.
研究的目的:
- 调查特拉佐的肝脏代谢稳定性和途径.
- 确定负责特拉佐代谢的CYP酶.
- 评估特拉佐及其活性代谢物mCPP对CYP酶的抑制作用.
主要方法:
- 在人类,小鼠和老鼠肝细胞中评估了代谢稳定性.
- 使用肝脏显微体,肝细胞和血进行了代谢分析.
- 确定了使用抑制剂和重组酶的参与CYP异型.
- 在人类和小鼠肝细胞中评估了trazodone和mCPP的CYP抑制.
主要成果:
- 特拉佐在内在清除中显示出显著的物种间差异.
- 人类肝细胞表现出最慢的代谢转化.
- CYP3A4是特拉佐代谢和mCPP形成的主要酶.
- CYP2D6,CYP2C19和FMO对其他代谢物形成作出了贡献.
结论:
- CYP3A酶是特拉佐代谢和mCPP形成的关键.
- 在CYP3A代谢和清除方面,物种间的差异是显著的.
- 人类特异性模型对于特征特拉佐的药理动力学至关重要.
- 研究结果支持在不同患者群体中优化临床使用.
更多相关视频
10:44Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
Published on: March 28, 2017
16:02Demonstration of the Sequence Alignment to Predict Across Species Susceptibility Tool for Rapid Assessment of Protein Conservation
Published on: February 10, 2023
相关概念视频
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
A study on guinea pigs examined the...
Factors Affecting Drug Biotransformation: Biological
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
Antidepressant Drugs: MAOIs and Other Agents
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug Biotransformation: Overview
Drug Biotransformation: Overview
![Radiosynthesis of 1-2-[18F]Fluoroethyl-L-Tryptophan using a One-pot, Two-step Protocol](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F63025.jpg&w=3840&q=50)